In case you missed it, Dr Kilian Kelly presented to brokers, fund managers, and high net-worth investors over lunch at the Establishment Ballroom, outlining Cynata's recent clinical trial milestones. Watch the presentation here:
Off the back of a string of positive announcements - DFU trial initial data, new CBO and first patient treated in aGVHD trial - Cynata CEO Dr Kilian Kelly sat down with Finance News Network to discuss The Company's milestones. Watch the interview below
In early March, the first patient was enrolled and treated in Cynata’s Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).
Learn more here: https://bit.ly/4b0nkG7
Cynata has updated the market on the positive progress of its diabetic foot ulcers clinical trial.
Read Stockhead’s coverage here https://bit.ly/3P0mb8N
Cynata is analysing wound surface areas in the first 16 patients of its Phase 1 trial for CYP-006TK, its off-the-shelf iPSC-derived MSC topical dressing for diabetic foot ulcers, with results expected by Q1 2024.